Contents

Search


selexipag (Uptravi)

Indications: - pulmonary hypertension Adverse effects: - headache - diarrhea - nausea/vomiting - jaw pain - myalgia - leg pain - flushing Mechanism of action: - IP prostacyclin receptor agonist - vasodilator agent - relaxes

Interactions

drug adverse effects of antihypertensive agents

General

pulmonary agent receptor agonist vasodilator agent

References

  1. FDA News Release. December 22, 2015 FDA approves new orphan drug to treat pulmonary arterial hypertension. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm478599.htm
  2. Sitbon O, Channick R, Chin KM et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015 Dec 24; 373:2522 PMID: 26699168 http://www.nejm.org/doi/full/10.1056/NEJMoa1503184